Scinai ends PC111 licensing deal, shifts R&D focus to NanoAb platform

Reuters2026/09/08 13:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Scinai Immunotherapeutics ended its PC111 option and license arrangements with PinCell, shifting R&D focus to its NanoAb platform.
Option conditions expired Aug. 31, 2026, triggering termination; no extension agreement was reached.
Move avoids new PC111 funding commitments, reallocating capital and management capacity toward its CDMO unit’s commercial execution.
NanoAb priorities include two IL-17 programs; intradermal psoriasis candidate seeks about EUR 12 million in Poland grant funding.
CDMO pipeline showed about USD 3.1 million in committed customer orders as of Aug. 16, 2026; 2026 revenue target remains about USD 5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scinai Immunotherapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609080918PR_NEWS_USPR_____LN42353) on September 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Scinai ends PC111 licensing deal, shifts R&D focus to NanoAb platform

You may also like

Crypto prices